aaim15 - indolent lymphoid disorders · 2015-10-14 · lymphoid disorders indolent: follicular...
TRANSCRIPT
![Page 1: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/1.jpg)
Indolent Lymphoid Disorders
Lazy nothingness or incurable lethality?
Michael Tees, MD, MPHHematology ~ Blood and Marrow Therapies
Colorado Blood Cancer Institute
![Page 2: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/2.jpg)
Objectives
Identify that indolent lymphomas should be considered indolent lymphoid disorders
Understand the mortality implications of the indolent lymphoid disorders depending on age, treatment, and other prognostic factors
Understand the long-term outcomes after hematopoietic cell transplantation
![Page 3: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/3.jpg)
Indolent Lymphoid Disorders
Review
What is indolent?
Disease management and implications
Survival and factors affecting mortality
![Page 4: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/4.jpg)
Indolent Lymphoid Disorders
Review
What is indolent?
Disease management and implications
Survival and factors affecting mortality
![Page 5: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/5.jpg)
Hematologic MalignanciesHematologic Disease US Incidence, 2015 estimate
Total 162,020
Myeloid
Acute Myeloid Leukemia 20,830
Chronic Myeloid Leukemia 6,660
Plasma Cell 26,850
Lymphoid
Acute Lymphocytic Leukemia 6,250
Hodgkin Lymphoma 9,050
Non-Hodgkin Lymphoma 71,850
Chronic Lymphocytic Leukemia 14,620
Source: American Cancer Society, 2015
![Page 6: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/6.jpg)
HematopoiesisHSC
MyeloidLymphoid
B T
NK
![Page 7: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/7.jpg)
Indolent Lymphoid Disorders
Review
What is indolent?
Disease management and implications
Survival and factors affecting mortality
![Page 8: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/8.jpg)
Hematologic MalignanciesHematologic Disease US Incidence, 2015 estimate
Total 162,020
Myeloid
Acute Myeloid Leukemia 20,830
Chronic Myeloid Leukemia 6,660
Plasma Cell 26,850
Lymphoid
Acute Lymphocytic Leukemia 6,250
Hodgkin Lymphoma 9,050
Non-Hodgkin Lymphoma 71,850
Chronic Lymphocytic Leukemia 14,620
Source: American Cancer Society, 2015
![Page 9: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/9.jpg)
Lymphoid Disorders
B-cell disorders: ~ 90%
T-cell disorders: ~ 10%
NK-cell disorders: ~ 1-2%
![Page 10: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/10.jpg)
Indolent: 1a: causing little or no pain1b: slow to develop or heal
2a: averse to activity, effort or movement2b: conducive to or encouraging laziness
Source: Mirriam-Webster Dictionary
Indolent Lymphoid Disorders
![Page 11: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/11.jpg)
Classic Thought
Indolent = incurable
Aggressive = potentially curable
![Page 12: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/12.jpg)
Classic Thought
Indolent: risk of progression
Aggressive: risk of relapse after treatment
![Page 13: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/13.jpg)
Classic Action
Indolent = Watch and Wait
Aggressive = Treat now!
![Page 14: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/14.jpg)
Lymphoid DisordersAggressive: DLBCLMediastinal Large B-cell LymphomaPrimary Effusion LymphomaHodgkin Lymphoma*Burkitt LymphomaPeripheral T-cell LymphomaNK cell Leukemia
Mantle Cell LymphomaHairy Cell Leukemia
![Page 15: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/15.jpg)
Lymphoid DisordersAggressive: DLBCLMediastinal Large B-cell LymphomaPrimary Effusion LymphomaHodgkin Lymphoma*Burkitt LymphomaPeripheral T-cell LymphomaNK cell Leukemia
Mantle Cell LymphomaHairy Cell Leukemia
TREAT NOW!
![Page 16: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/16.jpg)
Lymphoid Disorders
Indolent: Follicular LymphomaMarginal Zone LymphomasChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaLymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia* Nodular Lymphocyte-Predominant Hodgkin LymphomaPrimary Cutaneous Lymphoproliferative DisordersT-cell Large Granular Lymphocytic Leukemia (T-LGLL)Cutaneous T-Cell Lymphoma (Mycosis Fungoides/Sezary Syndrome)
![Page 17: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/17.jpg)
Indolent: Follicular LymphomaMarginal Zone LymphomasChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaLymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia* Nodular Lymphocyte-Predominant Hodgkin LymphomaPrimary Cutaneous Lymphoproliferative DisordersT-cell Large Granular Lymphocytic Leukemia (T-LGLL)Cutaneous T-Cell Lymphoma (Mycosis Fungoides/Sezary Syndrome)
Lymphoid DisordersWATCH AND WAIT
![Page 18: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/18.jpg)
Indolent: Follicular LymphomaMarginal Zone LymphomasChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaLymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia*Nodular Lymphocyte-predominant Hodgkin LymphomaPrimary Cutaneous Lymphoproliferative DisordersT-cell Large Granular Lymphocytic Leukemia (T-LGLL)Cutaneous T-Cell Lymphoma (Mycosis Fungoides/Sezary Syndrome)
Lymphoid DisordersWATCH AND WAIT
FOR WHAT?
![Page 19: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/19.jpg)
Indolent Lymphoid Disorders
Review
What is indolent?
Disease management and implications
Survival and factors affecting mortality
![Page 20: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/20.jpg)
Current Management
IndolentAggressive
![Page 21: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/21.jpg)
Indolent Lymphoid Disorders
How we decide to treat:
Symptoms or disease burden
Molecular/genetic determinants
Prognostication (FLIPI, MIPI, IPI, Rai)
![Page 22: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/22.jpg)
Follicular LymphomaFLIPI-2 Score
Age > 60 Hgb < 12 Bone marrow involvement beta-2 microglobulin elevated Longest diameter of largest LN > 6cm
Score 3-5 = approx 50-60% OS at 5 years
Source: Federico et al, J Clin Oncol 2009
Pathologic grading of disease (grade 1-2 vs 3)
![Page 23: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/23.jpg)
Follicular Lymphoma: GELF Criteria
• Involvement of ≥3 nodal sites, each with a diameter of ≥3 cm• Any nodal or extranodal tumor mass with a diameter of ≥7 cm• B symptoms• Splenomegaly• Pleural effusions or peritoneal ascites• Cytopenias (leukocytes <1.0 x 109/L and/or platelets <100 x 109/L) • Leukemia (>5.0 x 109/L malignant cells)
![Page 24: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/24.jpg)
(A) Progression-free survival (PFS) and (B) overall survival (OS) of the training sample (832 patients) according to the Follicular Lymphoma International Prognostic Index 2 (FLIPI2); (C) PFS and (D) OS of
the validation sample (231 patients) according to F...
Massimo Federico et al. JCO 2009;27:4555-4562
![Page 25: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/25.jpg)
Lymphoplasmacytic Lymphoma
HyperviscosityNeuropathyOrganomegalyAmyloidosisCold Agglutinin DiseaseCryoglobulinemiaCytopenias due to DiseaseBulky Adenopathy
![Page 26: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/26.jpg)
LGL Leukemia
Symptoms from autoimmune manifestations
Neutropenia with absolute neutrophil count < 500 or ANC > 500 with chronic infections
Transfusion dependent
Source: Tees et al. Treating rare lymphoprofliferative disorders: T-cell large granulocyte lymphocytic leukemia, J Int Hem Oncol 2014.
![Page 27: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/27.jpg)
CLL/SLLAge and functional status
Rai/Binet staging
Co-morbidities
FISH/cytogenetics (11q, 17p)
Source: Jain. Initial treatment of CLL: integrating biology and functional status, Blood 2015.
![Page 28: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/28.jpg)
Treatments of Choice
When watching and waiting is over…
![Page 29: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/29.jpg)
Treatments of Choice
Follicular Lymphoma:- CHOP-R (cyclophosphamide, vincristine, doxorubicin, prednisone, rituximab)- BR (bendamustine, rituximab)- R (rituximab)- Radiation Therapy
Marginal Zone Lymphoma:- similar to above
![Page 30: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/30.jpg)
Treatments of ChoiceLymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia:- Bortezomib +/- rituximab +/- prednisone- CHOP-R (Cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab)- Ibrutinib
Primary Cutaneous Lymphoproliferative Disorders (CD30+ Anaplastic Large Cell Lymphoma, Lymphomatoid Papulosis):- Surgical Excision and/or Radiation Therapy- Methotrexate- Pralatrexate- Brentuximab vedotin - CHOP or CHOEP (in ALCL with regional lymph nodes)- Phototherapy (Lymphomatoid papulosis)
![Page 31: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/31.jpg)
Treatments of ChoiceNodular Lymphocyte-predominant Hodgkin Lymphoma:- Radiation Therapy- Radiation + ABVD*(doxorubicin, bleomycin, vincristine, dacarbazine)- Radiation + CHOP +/- R (cyclophosphamide, vincristine, doxorubicin, prednisone, rituximab)- Radiation + CVP +/- R (cyclophosphamide, vincristine, prednisone, ritixumab)
T-cell LGLL:- Methotrexate +/- corticosteroids- Cyclophosphamide +/- corticosteroids- Cyclosporine
* Source: Savage KJ, Skinnider B, Al-Mansour M, et al. Treating limited stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 2011;118:4585-4590.
![Page 32: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/32.jpg)
Treatments of ChoiceCutaneous T-Cell Lymphomas (Mycosis Fungoides/Sezary Syndrome)- Topical steroids, chemotherapy, imiquimod, or retinoids- Local radiation- Phototherapy- Total skin electron beam therapy
CLL/SLL:- Chlorambucil + obinutuzumb/ofatumumab/rituximab- Bendamustine + rituximab- Fludarabine + rituximab- FCR (fludarabine, cyclophosphamide, rituximab)- PCR (pentostatin, cyclophosphamide, rituximab)
![Page 33: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/33.jpg)
Treatments of ChoiceMore on CLL/SLL
17p deletion is a marker of more aggressive disease. Treatment upfront is recommended. This type does not respond as well to chemotherapy/immunotherapy, however, it remains a first-line recommendation. Now:
Ibrutinib: Bruton tyrosine kinase (BTK) inhibitor GAME CHANGERIdelalisib: PI3 kinase (PI3K) inhibitor GAME CHANGER
BTK and PI3K inhibitors appear to negate the poor prognosis of del(17p)
![Page 34: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/34.jpg)
Treatment PrinciplesRituximab has prolonged overall survival when used in combination with other other chemotherapeutic agents
Then should we use rituximab early and not watch and wait?Source: Marcus R et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008.
![Page 35: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/35.jpg)
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky
follicular lymphoma: an open-label randomised phase 3 trial
Kaplan-Meier
curves for the 252
patients randomly assigned in the initial
three-arm study(A)
Time to start of new treatment, (B)
progression-free
survival, (C) overall survival, and (D)
time to histological
transformation. HR=hazard ratio.
Kirit M Ardeshna et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial Lancet Oncol 2014, 424–435
![Page 36: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/36.jpg)
Treatment Principles
After chemotherapy is initiated, rituximab maintenance is often used to prolong disease control.
![Page 37: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/37.jpg)
Treatment: when to transplant
Autologous Hematopoietic Cell Transplant
vs
Allogeneic Hematopoietic Cell Transplant
![Page 38: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/38.jpg)
Treatment: when to transplant
Autologous Hematopoietic Cell Transplant
vs
Allogeneic Hematopoietic Cell Transplant
![Page 39: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/39.jpg)
Treatment: when to transplant
In follicular lymphoma, if a patient has recurrence of disease within 12-24 months, autologous stem cell transplant is recommended
If a patient fails an autologous HCT, an allogeneic HCT is indicated
Source: Laport. Changing role of stem cell transplantation in follicular lymphoma. Hematology 2012.
![Page 40: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/40.jpg)
Treatment: when to transplant
What about the other indolents when disease has progressed?
![Page 41: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/41.jpg)
Treatment: when to transplant
Follicular LymphomaMarginal Zone LymphomasChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaLymphoplasmacytic Lymphoma/Waldenstrom’s MacroglobulinemiaNodular Lymphocyte-predominant Hodgkin LymphomaPrimary Cutaneous Lymphoproliferative DisordersT-cell Large Granular Lymphocytic Leukemia (T-LGLL)Cutaneous T-Cell Lymphoma (Mycosis Fungoides/Sezary Syndrome)
AUTO or ALLO
AUTO or ALLO
ALLO
ALLO
AUTO or ALLO
AUTO or ALLO
![Page 42: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/42.jpg)
Indolent Lymphoid Disorders
Review
What is indolent?
Disease management and implications
Survival and factors affecting mortality
![Page 43: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/43.jpg)
Mortality and Indolent Lymphoid Disorders: a perspective
Even in elderly with FL (> 80 years old in US), OS at 5 yrs is 59%, and only 38% of the deaths were from lymphoma
Anthracyclines are often removed from these treatments
Source: Nabhan et al, Brit J Hematol 2015.
![Page 44: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/44.jpg)
Mortality and Indolent Lymphoid Disorders
Common Risk Factors
Treatment-related complications and late effects
Transformation
![Page 45: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/45.jpg)
Common Risk Factors
Most prognostic utilities identify age 60 and older as a risk factor for poorer outcomes- the value of prognostic tools is that it combines risk. Age in of itself may not be a risk factor, but is associated with inferior outcomes
Time to Progression
![Page 46: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/46.jpg)
Time to Progression
Relapse/Progression by itself is not a good marker of prognosis.
The time to progression may be a better tool.
![Page 47: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/47.jpg)
Kirit M Ardeshna et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial Lancet Oncol 2014, 424–435
![Page 48: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/48.jpg)
Risk of Treatment(s)
The indolent nature of the disease = monitoring, treatment, monitoring, treatment…
![Page 49: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/49.jpg)
Risk of Treatment(s)
Source: Rohatiner. Myeloablative therapy with autologous bone marrow
transplantation for follicular lymphoma at the time of second and subsequent
remission: long term follow-up. J Clin Oncol 2007.
Transplant Outcomes: Follicular Lymphoma
![Page 50: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/50.jpg)
Late Effects of Therapy
Late toxicities are clinically relevant today
In the future, targeted therapy may remove some of the secondary effects of therapy
![Page 51: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/51.jpg)
Late Effects of Therapy
Radiation Therapy
Immunotherapy
Chemotherapy
![Page 52: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/52.jpg)
Late Effects of TherapyRadiation Therapy:- location-specific - may increase risk of breast cancer or
cardiomyopathy if administered to the chest/mediastinal region
- in general, this risk is less now with more precise technology
Immunotherapy: - PML
![Page 53: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/53.jpg)
Late Effects of TherapyChemotherapy:
Cardiac: - Anthracyclines: 5-10%
Pulmonary: - Bleomycin (in treatment of HL) 18%, median 5 yrs OS 63% vs 90% in those who did not develop
Sources: Silverman et al. Balancing cure and long-term effects in ALL,
Hematology 2014. Martin et al. Bleomycin pulmonary toxicity and outcomes in
Hodgkin lymphoma. J Clin Oncol 2005
![Page 54: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/54.jpg)
Late Effects of TherapySecondary malignancies:
– associated with total dose exposure – ALL LYMPHOMAS: 15 year cumulative risk 11.2% (< 50 yrs old 7%, > 50 yrsold 17.5%)- risk plateaus at around 15 yrs from
diagnosisSource: Mudie et al. Risk of secondary malignancies in NHL, J Clin Oncol 2006
![Page 55: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/55.jpg)
Late Effects of Transplant
Autologous:
-little long-term morbidity/mortality associated with regimens – complications can occur (acute kidney injury, arrhythmias) – risk of mortality attributed to transplant is approximately 1%
![Page 56: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/56.jpg)
Survival after autologous transplants for follicular lymphoma, 2002-2012
Available at CIBMTR.org
Source: Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides. Available at: http://www.cibmtr.org
![Page 57: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/57.jpg)
Survival after autologous transplants for mantle cell lymphoma, 2002-2012
Available at CIBMTR.org
Source: Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides. Available at: http://www.cibmtr.org
![Page 58: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/58.jpg)
Causes of Death after Autologous Transplants done in 2011-2012
Available at CIBMTR.org
Source: Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides. Available at: http://www.cibmtr.org
![Page 59: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/59.jpg)
Late Effects of TransplantAllogeneic:
- little morbidity/mortality associated with conditioning regimens itself, less total body irradiation is being used
- cardiovascular disease 10+ years post-transplant- Pulmonary (idiopathic pneumonia syndrome, bronchiolitis obliterans)- Skeletal events (avascular necrosis)- GVHD- many others…
![Page 60: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/60.jpg)
Late Effects of Transplant
Allogeneic: - Classify as either relapse mortality and
non-relapse mortality- Unfortunately, non-relapse mortality is
often used synonymously with transplant-related mortality
- Mortality within first year is affected by MANY variables
![Page 61: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/61.jpg)
Survival after allogeneic transplants for follicular lymphoma, 2002-2012
Available at CIBMTR.org
Source: Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides. Available at: http://www.cibmtr.org
![Page 62: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/62.jpg)
Survival after allogeneic transplants for CLL, 2002-2012
Available at CIBMTR.org
Source: Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides. Available at: http://www.cibmtr.org
![Page 63: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/63.jpg)
Causes of Death after HLA Match Sibling Transplants done in 2011-2012
Available at CIBMTR.org
Source: Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides. Available at: http://www.cibmtr.org
![Page 64: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/64.jpg)
Causes of Death after HLA Unrelated Donor Transplants done in 2011-2012
Available at CIBMTR.org
Source: Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides. Available at: http://www.cibmtr.org
![Page 65: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/65.jpg)
TransformationAll indolent lymphomas carry a risk of histologic transformation to an aggressive lymphoma
Follicular lymphoma, Marginal Zone Lymphoma, CLL have risk to transform to Diffuse Large B-cell Lymphoma
Nodular Lymphocyte-predominant Hodgkin Lymphoma has a risk to transform to aggressive Hodgkin Lymphoma
However, transformation can be any which way (FL -> Burkitt Lymphoma, CLL/SLL -> Hodgkin Lymphoma)
![Page 66: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/66.jpg)
Transformation
It is unclear if the risk of histologic transformation is already present and detectable at the time of diagnosis
Source: Montoto et al. Transformation of indolent B-cell lymphomas. J ClinOncol 2011.
![Page 67: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/67.jpg)
Transformation: Incidence
Disease Estimated Incidence
Follicular Lymphoma20% at 5yrs30% at 10yrs
CLL 16.2% at 10yrs
Lymphoplasmcytic Lymphoma 10% at 7yrs
All Indolent Lymphoid Disorders14% at 5yrs21% at 10yrs39% at 15yrs
Approximate 3% annual risk of transformation
Source: Freedman et al. Biology and Management of Histologic Transformation of Indolent Lymphoma, Hematology 2005.
![Page 68: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/68.jpg)
Transformation
When patients transform, his/her survival, despite prior therapies, appears to match patients with de novo aggressive lymphomas.
Source: Kuruvilla et al. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12, Blood 2015.
![Page 69: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/69.jpg)
Source: Kuruvilla et al. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12, Blood 2015.
![Page 70: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/70.jpg)
Summary
Indolent Lymphomas = Indolent Disorders
It is treatable and possibly curable
Our treatments pose mild risk of toxicity
The indolent lymphoid disorders can be both lazy and lethal
![Page 71: AAIM15 - Indolent Lymphoid Disorders · 2015-10-14 · Lymphoid Disorders Indolent: Follicular Lymphoma Marginal Zone Lymphomas Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://reader033.vdocuments.mx/reader033/viewer/2022052801/5f12b0cceda94976d470f862/html5/thumbnails/71.jpg)
Thank You
Michael Tees, MD, MPH
Twitter @ColoradoBlood | Facebook | LinkedIn
Indolent